An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Cadegiani et al., medRxiv, doi:10.1101/2020.10.05.20206870
https://c19early.org/cadegiani9.html